Introduction
Each year, hundreds of thousands of patients in the United States receive treatment with either fluorouracil or capecitabine (a pro-drug of fluorouracil) for a variety of malignancies, including multiple gastrointestinal malignancies and breast cancer (1) . Fluorouracil and capecitabine are cytotoxic antimetabolites that interfere with nucleic acid metabolism in both normal and cancer cells. Studies have reported an approximate 0.5% incidence of mortality from fluorouracil toxicity, and an estimated 0.5-1% of incidence of mortality from capecitabine-based regimens (2-7). While overdoses of these drugs are rare, they can result in significant morbidity and mortality. In addition, certain patients have impaired elimination of these drugs and therefore manifest with early-onset, severe or life-threatening toxicities that can result in death. One of the most well-described etiologies for impaired elimination of fluorouracil and capecitabine is a partial or complete deficiency of the enzyme dihydropyrimidine dehydrogenase (DPYD, also known as DPD), which is the initial rate-limiting enzyme in the catabolism of fluoropyrimidines (8) . DPD activity is subject to wide variability due in part to genetic variation in the sequence of the DPD gene (DPYD), which can result in a range of enzymatic deficiency from partial (~3-5% of the population) to complete loss (~0.2% of the population) of enzyme activity (9-10).
Unfortunately, prescreening of patients for "impaired" DPD activity prior to initiation of pyrimidine therapy is not routinely performed and is not yet possible with a high level of predictive accuracy using available genotyping and/or phenotyping tests (11). Prior to uridine triacetate, there were no approved therapies for patients experiencing serious or life-threatening toxicities after receiving fluorouracil or capecitabine. to intra-batch and inter-batch variability in the dissolution of the products were identified that could impact the absorption and availability of the drug. However, due to the demonstrated favorable benefit-risk and no known toxic dose, the variability was deemed acceptable, and a post-marketing commitment to confirm the dissolution studies and address these concerns was agreed upon.
Nonclinical Pharmacology and Toxicology
Uridine triacetate is a pyrimidine analogue and acetylated pro-drug of uridine. 
Clinical Pharmacology
Following single dose oral administration, the maximum uridine concentrations in plasma was achieved within 2-3 hours, and the half-life ranged from 2 to 2.6 hours. Mean uridine concentrations after 20 doses increased approximately 1.5 times in the clinical trials. Food did not impact the pharmacokinetics of uridine, and uridine triacetate can be administered without regard to meals. When necessary, uridine triacetate can be administered via a nasogastric or gastrostomy tube.
Uridine can be excreted via the kidneys and can also be metabolized by normal pyrimidine catabolic pathways present in most tissues. In vitro enzyme data did not reveal meaningful effects of uridine triacetate or uridine on cytochrome P450 inhibition or induction. In vitro data showed that uridine triacetate was a weak substrate for P-glycoprotein (ABCB1, also known as P-gp). Due to the potential for high concentrations of uridine triacetate in the gut after dosing, the interaction of uridine triacetate with orally administered P-gp substrate drugs cannot be ruled out. There is no clinically meaningful effect of gender, race and age on uridine PK in adults, and no dose adjustment is needed based on these intrinsic factors. Although there was a trend for increase in clearance of uridine triacetate with increasing body surface area (BSA) in 
Demographics and Disease Characteristics
Research. 
The majority of patients enrolled in the two trials were White (72%), 9% were Black/African American, 6% were Hispanic, 4% were Asian and 95% had a cancer diagnosis.
The median age was 59 years (range: 1 to 83). A total of six pediatric patients were administered uridine triacetate. Of the 135 patients, 117 were treated with uridine triacetate following an overdose of fluorouracil (n=112) or capecitabine (n=5), and 18 were treated after exhibiting early-onset, severe or life-threatening toxicities within 96 hours following the end of therapy (see Figure 1) . Of the 112 patients overdosed with fluorouracil, 105 (94%) were overdosed by infusion rate only (range 1.3 to 720 times the planned infusion rate), four (4%) were overdosed by dose only, and three (3%) were overdosed by both dose and rate. These fluorouracil overdoses occurred most frequently from incorrect programing of the infusion pump (42%) or pump malfunctions (23%). Of the patients who exhibited impaired elimination, the severe or lifethreatening toxicities seen involved the central nervous system (e.g. encephalopathy, acute mental status change), cardiovascular system, gastrointestinal system (e.g. mucositis), and bone marrow (e.g. neutropenia).
Efficacy Results
Of the 135 patients treated with uridine triacetate in the two trials, 96% (n=130) survived to day 30 or resumed chemotherapy prior to day 30, and 4% (n=5) died. As shown in Table 1 cases for fluorouracil and 145 cases for capecitabine) were described; many cases demonstrated a similar presentation of early-onset, severe or life-threatening toxicity which was treated with supportive care but ultimately all resulted in death.
Safety Results
The primary safety population included 135 patients who received at least one dose of uridine triacetate. Five patients died within 30 days of therapy, although none of the deaths were attributed to uridine triacetate. Three of the deaths occurred in patients who overdosed with fluorouracil and two deaths occurred in patients exhibiting early onset, severe or life-threatening toxicity after fluorouracil administration.
Although the safety review was confounded by adverse events related to fluorouracil or capecitabine, uridine triacetate was overall well tolerated by most patients. Only two patients discontinued uridine triacetate due to adverse reactions (nausea, vomiting, and diarrhea) based on timing of the reaction with uridine triacetate administration. Serious adverse reaction and Grade ≥ 3 adverse reactions were seen in only one patient treated with uridine triacetate (Grade 3 nausea and vomiting). Common (Grade 1-2) adverse reactions occurring in >2% of patients treated with uridine triacetate included vomiting, nausea, and diarrhea.
Discussion
The approval of uridine triacetate was based on two open-label, single arm trials and highlights the ability of FDA to approve a drug based on data obtained from expanded-access Although there were only six pediatric patients studied on one of the trials, all of the patients survived. The safety profile demonstrated a low risk to pediatric patients with only mild toxicities seen. Therefore, due to the cases studied, supportive non clinical safety information, adult clinical data, and a strong biologic and clinical rationale, the pediatric indication was included. Similarly, only five capecitabine treated patients were studied on the trials. However, all of these patients survived, and based upon the understanding of capecitabine as a pro-drug of fluorouracil, as well as additional capecitabine patient cases submitted in the 120-day safety report demonstrating definitive uridine triacetate benefit, the indication included capecitabine.
The patients with early-onset, severe or life-threatening toxicity from fluorouracil were closely examined, as there is a potential risk that using uridine triacetate in a non-emergent setting for patients who experience usual toxicities of fluorouracil or capecitabine might result in decreased efficacy of fluorouracil or capecitabine. To address this concern, the timing of earlyonset toxicities (within 96 hours) and a detailed description of the expected affected organ systems with potential severe or life-threatening toxicities were described in the indication statement. In addition, a limitation of use was added to further highlight this potential risk.
The subset of patients studied with early-onset, severe or life-threatening toxicity from fluorouracil was further examined in relation to DPD deficiency. Although 19 patients in the two trials were tested for DPD deficiency (nine patients had variants in DPYD, with four having genotypes often associated with complete or partial DPD deficiency), the available genetic testing results could not definitively account for the early-onset, severe or life-threatening toxicities from fluorouracil or capecitabine administration. This may be in part due to the inconsistencies introduced by the use of different tests with differing methods and alleles assayed, as well as the unclear functional impact of some of the variants identified. In addition, there were also cases of early-onset toxicity which did not have a DPYD variant identified and cases for which no testing was performed. For these reasons, no specific description of DPD deficiency was included in the label.
In conclusion, uridine triacetate demonstrated efficacy for the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or of patients who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration. In addition, there were supportive nonclinical data and a safety profile that was acceptable and low-risk. Despite small numbers in certain subgroups such as early-onset toxicity, capecitabine treated patients, and pediatric patients, the overall benefit: risk profile was favorable to support approval. The approval demonstrates FDA's 
